NextFin News - Whoop, the Boston-based wearable technology firm, has secured $575 million in a Series G funding round that values the company at $10.1 billion, nearly tripling its previous valuation of $3.6 billion. The capital injection, announced Tuesday, marks a significant escalation in the battle for the "human performance" market, drawing support from a diverse coalition of sovereign wealth funds, medical institutions, and global sports icons including Cristiano Ronaldo and LeBron James.
The round was led by Collaborative Fund, with participation from Abu Dhabi’s Mubadala Investment Company and the Qatar Investment Authority. Notably, the inclusion of medical device giant Abbott and the Mayo Clinic signals a strategic pivot for Whoop, moving beyond its origins as a niche tool for elite athletes toward a broader role in clinical healthcare. Founder and CEO Will Ahmed confirmed that the company exited 2025 with a $1.1 billion bookings run rate, representing 103% year-over-year growth.
Ahmed’s emphasis on "bookings" rather than traditional revenue highlights the unique financial friction of the wearable sector. Unlike pure software-as-a-service (SaaS) models, Whoop must balance the capital-intensive nature of hardware manufacturing and global logistics with the recurring revenue of its subscription-only model. This complexity often leads to divergent views on valuation. While the $10.1 billion figure suggests a roughly 9x multiple on bookings, some private market analysts remain cautious about whether such a premium can be sustained as the company moves into the more regulated and slower-moving healthcare space.
The valuation surge comes as rival Oura is reportedly interviewing banks for a potential initial public offering later this year. While Ahmed stated that Whoop is performing the "no-regrets work" necessary to become a public entity, he stopped short of committing to a 2026 listing. The company intends to deploy the new capital toward international expansion and research into artificial intelligence integrations that can provide more predictive health insights.
However, the path to a successful IPO is not without hurdles. The consumer electronics market is notoriously fickle, and Whoop faces intensifying competition from tech giants like Apple and Google-owned Fitbit, which have increasingly integrated advanced health sensors into their mass-market devices. Critics argue that Whoop’s screenless design, while a differentiator for purists, may limit its appeal to a broader consumer base that expects smartwatch functionality alongside health tracking.
The involvement of Abbott is perhaps the most consequential detail of the Series G. By aligning with a leader in glucose monitoring and medical diagnostics, Whoop is positioning itself to bridge the gap between fitness tracking and chronic disease management. Whether this transition justifies a decacorn valuation will depend on the company's ability to convert its high-performance brand equity into a clinical-grade data platform that doctors and insurers can trust.
Explore more exclusive insights at nextfin.ai.
